Reproducible erythroid aplasia caused by mycophenolate mofetil.
Anemia secondary to mycophenolate mofetil (MMF) was recently described in experimental animals. A clinical association between MMF and anemia has been observed, but there are no proven reports. We describe a girl with chronic graft failure who developed erythroid aplasia under immunosuppression with MMF. She showed prompt resolution when MMF was discontinued and a recurrence of this clinical course when MMF was restarted. As re-challenge with a medication is the most definitive approach for showing a direct relationship between the drug and the side effect, this case clearly demonstrates that MMF can cause erythroid aplasia.
Arbeiter
K
K
Department of Pediatrics, Vienna Medical School AKH Wien, Vienna, Austria.
Greenbaum
L
L
Balzar
E
E
Müller
T
T
Hofmeister
F
F
Bidmon
B
B
Aufricht
C
C
D000293:Adolescent; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000209:etiology; D016030:Kidney Transplantation; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011183:Postoperative Complications; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced*
D009173:Mycophenolic Acid